Finance

Beta
Lists
SMMT:NASDAQ
Summit Therapeutics Inc
$14.25
-0.21%
(-0.030) 1D
$14.20
-0.35% (-0.050)
Pre-market
Closed: Jun 23, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SMMT...
Open
$13.93
High
$14.81
Low
$13.93
Mkt. cap
11.06B
Avg. vol.
5.95M
Volume
1.82K
52-wk high
$30.98
52-wk low
$12.55
EPS
-$1.60
Beta
-1.32
Shares outstanding
776.16M
No. of employees
265
Open
$13.93
High
$14.81
Low
$13.93
Mkt. cap
11.06B
Avg. vol.
5.95M
Volume
1.82K
52-wk high
$30.98
52-wk low
$12.55
EPS
-$1.60
Beta
-1.32
Shares outstanding
776.16M
No. of employees
265
News stories
From sources across the web
About Summit Therapeutics Inc
CEORobert Duggan | Maky Zanganeh
Employees265
Founded2003
Headquarters-
SectorBiotechnology
Websitesmmttx.com
Analyst Ratings
Based on 13 analysts giving stock ratings to SMMT in the past 3 months
Buy
Buy
8
Hold
4
Sell
1
12 month forecast
Based on 13 Wall Street analysts offering 12 month price targets for SMMT in the last 3 months.
Highest
Current $14.25
$45.00 (+215.79%)
Average
$29.25 (+105.26%)
Lowest
$9.80 (-31.23%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Jeffrey Walch
Bernstein
Sell
Reiterated
$9.80
-31.2%
06/21/2026
Etzer Darout
Barclays
Hold
Maintained
$18.00
+26.3%
06/02/2026
Dara Azar
Stifel Nicolaus
Buy
Maintained
$45.00
+215.8%
06/01/2026
Bradley Canino
Guggenheim
Buy
Maintained
$40.00
+180.7%
06/01/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$40.00
+180.7%
05/31/2026
Mohit Bansal
Wells Fargo
Buy
Reiterated
$30.00
+110.5%
06/02/2026
Mitchell Kapoor
H.C. Wainwright
Hold
Reiterated
-
-
06/01/2026
Unknown Analyst
Bernstein
Sell
Initiated
$7.70
-46%
05/21/2026
Faisal Khurshid
Jefferies
Hold
Maintained
$17.00
+19.3%
05/21/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/06/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
$34.00
+138.6%
05/01/2026
Salveen Richter
Goldman Sachs
Buy
Maintained
$41.00
+187.7%
05/01/2026
Kelsey Goodwin
Piper Sandler
Hold
Maintained
$16.00
+12.3%
05/01/2026
William Maughan
Clear Street
Buy
Maintained
$31.00
+117.5%
05/01/2026
Stephen Willey
Stifel Nicolaus
Buy
Initiated
$45.00
+215.8%
04/08/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
$35.00
+145.6%
02/24/2026
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
208.02M
131.10M
147.29M
132.62M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
360.42M
103.12M
77.63M
62.59M
Operating expense
568.44M
234.21M
224.92M
195.21M
Total operating expenses
568.44M
234.21M
224.92M
195.21M
Operating income
-568.44M
-234.21M
-224.92M
-195.21M
Other non operating income
-53.00K
-
-
-
EBT including unusual items
-565.71M
-231.79M
-219.17M
-189.42M
EBT excluding unusual items
-565.71M
-231.79M
-219.17M
-189.42M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-565.71M
-231.79M
-219.17M
-189.42M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
2.98M
2.78M
5.88M
5.85M
Interest expense
-
-
-
-
Net interest expenses
2.98M
2.78M
5.88M
5.85M
Depreciation and amortization charges
-
-
-
-
EBITDA
-568.40M
-234.17M
-224.88M
-195.17M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer